Table 5.
Sub-analysis of the association of Val16Ala with 10-year breast cancer survival by specific chemotherapy regimen
| Therapy* | Univariate | Multivariate$ | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | n | HR (95% CI) | P-value | n | |
| Doxorubicin monotherapy (n=86) | ||||||
| Val/Val | 1 (ref.) | 22 | 1 (ref.) | 22 | ||
| Val/Ala | 0.65 (0.30–1.45) | 0.300 | 43 | 0.70 (0.31–1.61) | 0.402 | 43 |
| Ala/Ala | 1.73 (0.77–3.87) | 0.180 | 21 | 2.03 (0.84–4.87) | 0.115 | 21 |
| Val/Ala & Ala/Ala | 0.95 (0.47–1.92) | 0.893 | 64 | 1.05(0.50–2.20) | 0.892 | 64 |
| Ptrend | 0.189 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 65 | 1 (ref.) | 65 | ||
| Ala/Ala | 2.18 1.12–4.22) | 0.020 | 21 | 2.35 (1.18–4.66) | 0.015 | 21 |
| Cyclophosphamide/Doxorubicin or Cyclophosphamide/Doxorubicin/5-FU (n=63) | ||||||
| Val/Val | 1 (ref.) | 21 | 1 (ref.) | 18 | ||
| Val/Ala | 2.61 (0.71–9.51) | 0.145 | 32 | 2.49 (0.39–15.8) | 0.330 | 28 |
| Ala/Ala | 6.33 (1.58–25.7) | 0.010 | 10 | 139.5 (2.77–7017) | 0.013 | 8 |
| Val/Ala & Ala/Ala | 3.37 (0.98–11.59) | 0.054 | 42 | 2.60 (0.54–12.5) | 0.233 | 36 |
| Ptrend | 0.005 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 53 | 1 (ref.) | 46 | ||
| Ala/Ala | 3.51 (1.32–9.33) | 0.012 | 10 | 16.1 (3.22–80.3) | 0.001 | 8 |
| Mitomycin/5-FU (n=35) | ||||||
| Val/Val | 1 (ref.) | 8 | 1 (ref.) | 8 | ||
| Val/Ala | 2.44 (0.52–11.4) | 0.256 | 19 | 2.80 (0.54–14.4) | 0.218 | 19 |
| Ala/Ala | 1.62 (0.27–9.75) | 0.598 | 8 | 1.91 (0.26–13.9) | 0.521 | 8 |
| Val/Ala & Ala/Ala | 2.20 (0.49–9.85) | 0.305 | 27 | 2.20 (0.47–10.3) | 0.316 | 27 |
| Ptrend | 0.797 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 27 | 1 (ref.) | 27 | ||
| Ala/Ala | 0.79 (0.22–2.85) | 0.721 | 8 | 0.57 (0.14–2.26) | 0.428 | 8 |
| Cyclophosphamide/Methotrexate/5-FU (n=77) | ||||||
| Val/Val | 1 (ref.) | 14 | 1 (ref.) | 14 | ||
| Val/Ala | 3.05 (0.69–13.4) | 0.141 | 41 | 2.15 (0.45–10.3) | 0.338 | 36 |
| Ala/Ala | 6.02 (1.35–26.8) | 0.018 | 22 | 24.27 (2.84–207) | 0.004 | 19 |
| Val/Ala & Ala/Ala | 3.99 (0.95–16.8) | 0.059 | 63 | 4.61 (1.06–20.1) | 0.042 | 55 |
| Ptrend | 0.004 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 55 | 1 (ref.) | 50 | ||
| Ala/Ala | 2.53 (1.21–5.26) | 0.013 | 22 | 4.17 (1.77–9.81) | 0.001 | 19 |
*
11 patients who received doxorubicin and 3 patients who received cyclophosphamide as part of other therapy regimens than described were not included in the analyses
$
Cox Proportional-Hazards regression with adjustments for age at diagnosis, study site, race, tumor size, tumor grade, nodal involvement, p53 mutation and estrogen receptor status